Loading…
CRON
Cronos Group Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 22717L101
$3.45+1.62%Price as of Oct 23, 00:54 UTC · updated once a day, after the close
At a glance
Cronos Group Inc. (CRON) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Stayner, Canada and has 610 employees. The company is worth $1.27B and trades at 18.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $146.59M in fiscal 2025, up 24.6% from the year before. It reported a net loss of $9.45M. The share price is 4.5% below its 52-week high of $3.61. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $4.84M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $1.27B
- P/E
- 18.1x
- Forward P/E
- —
- P/B
- 1.2x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.19
- ROE
- 7.05%
- Profit margin
- 39.08%
- Revenue growth
- +58.40%
- Beta
- 1.20
- 52-week high
- $3.61
- 52-week low
- $2.28
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -29.1% over 5Y.
today you would have $618.50▼ -38.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.63 | $2.02 | $2.09 | $2.54 | $3.92 | $6.94 | $7.67 | $10.39 | |
| P/E | — | — | 18.4x | — | — | — | — | 2.3x | — |
| P/S | 17.0x | 6.8x | 6.6x | 9.1x | 11.1x | 22.8x | 53.5x |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$3.51
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$4.61
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$2.10
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TYRATyra Biosciences, Inc. | $18.52 | — | 3.1x | 0.00% | -45.31% | $1.27B |
| NUTXNutex Health Inc. | $186.10 | 7.4x | 3.2x | 0.00% | 64.56% | $1.27B |
| FRNMFreenome, Inc. | $11.75 | — | — | 0.00% | — | $1.26B |
| GHRSGH Research PLC | $18.15 |
About the company
- 610
- Stayner, Canada